Cargando…
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2–69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and...
Autores principales: | Nowak, A K, Byrne, M J, Williamson, R, Ryan, G, Segal, A, Fielding, D, Mitchell, P, Musk, A W, Robinson, B W S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376155/ https://www.ncbi.nlm.nih.gov/pubmed/12189542 http://dx.doi.org/10.1038/sj.bjc.6600505 |
Ejemplares similares
-
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002) -
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014) -
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014) -
Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008) -
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
por: Creaney, J, et al.
Publicado: (2001)